Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

Immunovant Inc. is focused on developing IMVT-1402, an inhibitor of the neonatal fragment crystallizable receptor (FcRn), which aims to address autoimmune diseases characterized by high pathogenic immunoglobulin G (IgG) antibody levels, potentially tapping into substantial market opportunities in generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company anticipates significant global peak sales for the gMG market, conservatively projecting $775 million at a 15% market penetration, bolstered by its superior self-administration auto-injector, which enhances patient compliance and minimizes healthcare costs. Furthermore, the strategic investment in R&D, reflected in the year-over-year increase in expenses, is expected to facilitate advancements in clinical efficacy and safety for batoclimab compared to competing treatments, positioning Immunovant favorably within a competitive landscape.

Bears say

The financial data for Immunovant Inc indicates a substantial year-over-year increase in research and development (R&D) expenses, which surged by 95.5% to $94.5 million, reflecting unsustainable growth in operational costs relative to the company’s projected financial health. A concerning aspect of their results is the posted loss per share of $0.76, which represents a significant deterioration from the prior year's loss of $0.36 and remains below estimates, suggesting ongoing financial strain despite heightened R&D investment. Additionally, the company faces multiple operational risks, including potential setbacks in clinical trials, regulatory challenges, and the emergence of new competitors that could hinder its progress in the competitive landscape of autoimmune disease treatment.

Immunovant Inc (IMVT) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 22 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.